Jonathan Demchick

Analyst Jonathan Demchick works with a stock forecast success ratio of 85.71% fulfilled within 278.5 days on average. Previously, Jonathan Demchick worked at MORGAN STANLEY.

Jonathan Demchick’s has documented 34 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on NUVA, NuVasive at 04-Aug-2023.

Wall Street Analyst Jonathan Demchick

Analyst best performing recommendations are on GMED (GLOBUS MEDICAL).
The best stock recommendation documented was for NUVA (NUVASIVE) at 5/31/2023. The price target of $40 was fulfilled within 12 days with a profit of $1.84 (4.82%) receiving and performance score of 4.02.

Average potential price target upside

• of $6.48 (13.85%) on GMED (GLOBUS MEDICAL).
• of $4.73 (7.98%) on IART (INTEGRA LIFESCIENCES HOLDINGS).
• of $3.66 (9.17%) on NUVA (NUVASIVE).